# Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct01819129` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01819129](<https://clinicaltrials.gov/study/NCT01819129>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01819129

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 881 participants.

## Technical summary

Registry record NCT01819129. Randomized; double masking; primary purpose treatment. Start 2013-09-09 (actual); primary completion 2015-01-22 (actual). Results posted on 2017-12-05.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 881 participants (enrolled count; ClinicalTrials.gov record NCT01819129, source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)
- Started: 2013-09-09 (actual) (ClinicalTrials.gov record NCT01819129, source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)
- Primary completion: 2015-01-22 (actual) (ClinicalTrials.gov record NCT01819129, source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)
- Completion: 2015-01-22 (actual) (ClinicalTrials.gov record NCT01819129, source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)
- Results first posted: 2017-12-05 (ClinicalTrials.gov record NCT01819129, source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)
- Countries: United States; Canada; Croatia; India; Israel; Puerto Rico; Russia; Serbia; Slovakia; United Kingdom (ClinicalTrials.gov record NCT01819129, source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01819129-2019-01-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
- Acronym: onset® 2
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Faster-acting insulin aspart
- Intervention (Drug): Insulin aspart
- Intervention (Drug): Insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial (`cardio:pubmed-28483786`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d0565dc4a18db0de27fc17bcb65d03e917bd8e896202d436cd162039512c990e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
